Prospective Study About the Association of Radiotherapy and Cetuximab in the Treatment of Epidermoid Cancers, Locally Advanced, of the Head and Neck.
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Epidermoid Head and Neck Cancer
Both
Epidermoid Head and Neck Cancer
Trial Information
Prospective Study About the Association of Radiotherapy and Cetuximab in the Treatment of Epidermoid Cancers, Locally Advanced, of the Head and Neck.
Inclusion Criteria:
- Age > 18 years
- Epidermoid head and neck carcinoma locally advanced
- Indication of Cetuximab and radiotherapy
- Karnofsky >= 60
- Patients participating to another compatible study could be included after
consultation with the study director Patients could be beforehand treated for an
other ORL cancer
The radiotherapy will be delivered for curative aim (minimal dose 66 Gy)
Exclusion Criteria:
- other histology
- Metastatic disease
- Recurrent patients
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Skin toxicities
Outcome Description:
according to NCI-CTCAE version 3.0
Outcome Time Frame:
until week 38
Safety Issue:
No
Principal Investigator
Eric LARTIGAU, MD PhD
Investigator Role:
Study Director
Investigator Affiliation:
Oscar Lambret Center
Authority:
France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
Study ID:
ESPACE
NCT ID:
NCT01647555
Start Date:
November 2006
Completion Date:
November 2013
Related Keywords:
- Epidermoid Head and Neck Cancer
- Cetuximab
- radiotherapy
- epidermoid head and neck cancer
- Head and Neck Neoplasms
Name | Location |
|---|
